Alto Neuroscience ANRO Deferred offering and share issue costs not yet paid
Deferred offering and share issue costs not yet paid at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept alto:DeferredOfferingAndShareIssueCostsNotYetPaid.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's deferred offering and share issue costs not yet paid.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's deferred offering and share issue costs not yet paid?
- Alto Neuroscience (ANRO) reported deferred offering and share issue costs not yet paid of $0 in Q1 2026.
- How has Alto Neuroscience's deferred offering and share issue costs not yet paid changed year-over-year?
- Alto Neuroscience's deferred offering and share issue costs not yet paid decreased by 100.0% year-over-year, from $138K to $0.
- What does deferred offering and share issue costs not yet paid mean?
- Represents costs incurred in connection with equity offerings that have been accrued but not yet paid in cash. This metric serves as a bridge between accounting accruals and actual cash outflows related to capital raising activities. Monitoring this helps investors understand pending liabilities that will impact future cash flow from financing activities.